Filing Flows

Filing Flows › Cryoport (CYRX) › Q3 2025

Cryoport (CYRX) Q3 2025 earnings results (third quarter 2025)

10-Q filed Nov 6, 2025

Cryoport (CYRX) reported revenue of $44.2M for the third quarter 2025 (Q3 2025), +15% from a year earlier and -3% from the quarter before. Operating margin was -22.5%, net loss $6.9M (15.7% of revenue).

Revenue$44.2M
Year over year+15%
Quarter over quarter-3%
Operating margin-22.5%
Net earnings−$6.9M

Cryoport, Q3 2025: revenue $44.2M (+15% year over year), operating margin -22.5%, net loss $6.9M, operating cash flow $2.2M. The chart follows the revenue to costs, profit and cash.

Q3 2025AmountQ/QY/Y
Revenue$44.2M-3%+15%
Operating profit−$9.9M——
Net earnings−$6.9M-106%—
Operating cash flow$2.2M—+389%

What changed

Revenue was $44.2M in Q3 2025, up 15% year over year and down 3% from the previous quarter. Product was the largest line at 45% of revenue. Product added $2.6M year over year (up 15%), 44% of the total change.

Gross margin was 48.2%, up 2.7 points from a year earlier. Operating costs exceeded revenue by $9.9M, an operating margin of -22.5%. Operating expenses grew 1% against revenue growth of 15%. The quarter ended with a net loss of $6.9M, after a profit of $108.9M the previous quarter. Non-operating items added $3.2M, -47% of pre-tax earnings, so the bottom line overstates operating performance.

Operating cash flow was $2.2M (up 389% year over year). Non-cash charges added back $6.4M of depreciation and amortization and $2.5M of share-based compensation. Working capital and other items added $190K. Capital expenditures of $3.5M exceeded it, leaving free cash flow of −$1.3M.

Questions

What was Cryoport's revenue in the third quarter 2025?

Cryoport (CYRX) reported revenue of $44.2M for the third quarter 2025 (Q3 2025), +15% from a year earlier and -3% from the quarter before.

Was Cryoport profitable in the third quarter 2025?

Operating loss was $9.9M (-22.5% of revenue) and net loss $6.9M.

Open the interactive Sankey →

Source: Cryoport 10-Q on SEC EDGAR.